A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Molecular Insight Pharmaceuticals, Inc.105 enrolled

Overview

This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic lymph node cancer. Comparative performance characteristics between MIP 1404 imaging and MRI were also assessed, as judged by histopathology results.

This is a single arm, open label study of approximately 100 high-risk prostate cancer patients scheduled for prostatectomy and extended pelvic lymph node dissection. Patients receive a single IV dose of 99mTc-MIP-1404 (study drug) followed by SPECT/CT scan 3-6 hours after injection. As standard of care, patients will undergo prostatectomy and extended pelvic lymph node dissection (EPLND) within three weeks of study drug dosing. 99mTc-MIP-1404 image data will be evaluated for visible uptake and compared with histopathology.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

105

Conditions

Prostate Cancer

Interventions

Drug: 99mTc-MIP-1404DRUG

A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404

Eligibility

Sex: MALEMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male aged 21 years or older. * Ability to provide signed informed consent and willingness to comply with protocol requirements. * Biopsy confirmed presence of adenocarcinoma of the prostate gland. * At high-risk for metastatic disease by a stage of cT3, cT4, or a total nomogram score of greater than or equal to 130. * Scheduled to undergo radical prostatectomy with extended pelvic lymph node dissection. * Agree to use an acceptable form of birth control for a period of 7 days after the 99mTc MIP-1404 injection. Exclusion Criteria: * Participating would significantly delay the scheduled standard of care therapy. * Administered a radioisotope within 5 physical half lives prior to study drug injection. * Have any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study. * Have a contraindication for MR imaging.

Locations (35)

Outcomes

Primary Outcomes

Assess the Ability of 99mTc-MIP-1404 to Detect Prostate Cancer Within the Prostate Gland.

For the prostate gland, sensitivity values refer to the number of subjects in the study, i.e., the percentages of true positive subjects correctly identified by the imaging technique. Pathology results were used as the truth standard for all imaging analyses.

Time frame: Within 3-6 hours of dosing SPECT/CT images will be taken

Secondary Outcomes

Assess the Ability of MIP-1404 to Detect Metastatic Prostate Cancer Within Pelvic Lymph Nodes

For lymph nodes, sensitivity values refer to the number of subjects in the study, i.e., the percentages of true positive subjects correctly identified by the imaging technique. Pathology results were used as the truth standard for all imaging analyses.

Time frame: Within 3-6 hours of dosing SPECT/CT images will be taken

Assess the Ability of MIP-1404 to Detect the Extent and Location of Prostate Cancer Within the Prostate Gland

For specific segments of the prostate, a sensitivity value refers to the number of evaluable segments (histologically examined "tissue-segments") from all subjects, i.e., the percentages of true positive segments correctly identified by the imaging technique.

Time frame: Within 3-6 hours of dosing SPECT/CT images will be taken

Assess the Ability of MIP-1404 to Detect the Specific Location of Metastatic Prostate Cancer Within Anatomic Pelvic Lymph Node Regions

For specific segments of the lymph nodes, a sensitivity value refers to the number of evaluable segments (histologically examined "tissue-segments") from all subjects, i.e., the percentages of true positive segments correctly identified by the imaging technique.

Time frame: Within 3-6 hours of dosing SPECT/CT images will be taken

Assess the Comparative Performance of MIP-1404 Against MRI for Detection of Prostate Cancer Within the Prostate Gland.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

City of Hope National Cancer Center

Duarte, California, United States

Mayo Clinic

Rochester, Minnesota, United States

New York Presbyterian Hospital - Cornell

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

Glickman Urology & Kidney Institute, Cleveland Clinic

Cleveland, Ohio, United States

Thomas Jefferson University / Jefferson Urology Associates

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Texas Vanguard Urologic Research Foundation

Houston, Texas, United States

University of Washington School of Medicine

Seattle, Washington, United States

University of Wisconsin

Madison, Wisconsin, United States

...and 25 more locations